Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Gastrointestinal Cancer Surgery
share announcement

Gastrointestinal Cancer Surgery

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 3317

Special Issue Editors

Dr. Florian Primavesi

E-Mail Website
Guest Editor
Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria
Interests: gastrointestinal and hepatobiliary cancers; surgical oncology; minimally invasive surgery; complication management; liver function and post-hepatectomy liver failure; targeted therapies; precision medicine; precision surgery
Dr. Daniel Neureiter

E-Mail Website
Guest Editor
Uniklinikum Salzburg, Landeskrankenhaus, Universitätsinstitut für Pathologie der PMU, Cancer Cluster Salzburg, 5020 Salzburg, Austria
Interests: cancerogenesis; epigenetics; histone deacetylases; miRNA; gastrointestinal tract; hepatopancreatic cancer; epithelial-mesen-chymal-transition; targeted therapy; tumor regression; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

These are exciting times for surgeons, interventional and medical oncologists, pathologists and all other specialties involved in treating cancer patients. While personalized medicine is revolutionizing therapeutic strategies for gastrointestinal, hepatobiliary and pancreatic malignancies, precision surgery including robotics, augmented reality and artificial intelligence will, within this decade, drastically change the way we approach abdominal cancers.

We invite you to participate in this Special Issue of Cancers focusing on gastrointestinal cancer surgery and related fields, which aims to include all aspects related to colorectal, stomach and small bowel malignancies, as well as pancreatic, liver and biliary tract cancer. Contributions exploring the latest advancements in our understanding of the pathogenesis, diagnosis, treatment, and prevention of these malignancies are particularly encouraged. Potential topics may include, for example, the following:

  • Surgical techniques, perioperative strategies, outcomes and complication management of gastrointestinal and HPB cancers;
  • Pathology and molecular biology of gastrointestinal, hepatobiliary and pancreatic malignancies;
  • Conventional, minimally invasive and interventional local treatment approaches;
  • Personalized medicine and precision surgery;
  • Robotics, augmented reality, artificial intelligence and big data in surgical oncology.

We look forward to your valuable contributions!

Dr. Florian Primavesi
Dr. Daniel Neureiter
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal cancer surgery
  • precision surgery
  • personalized medicine
  • robotics
  • pathology
  • colorectal cancer
  • stomach cancer
  • pancreatic cancer
  • hepatocellular cancer
  • biliary tract cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 218 KiB  
Article
Inflammatory Fibroid Polyp (Vanek’s Tumor): A Retrospective Multicentric Analysis of 67 Cases
by Mario Martín Sánchez, Víctor Domínguez-Prieto, Siyuan Qian Zhang, Hernán Darío Quiceno Arias, María Bernarda Álvarez Álvarez, Montiel Jiménez Fuertes, Cecilia Meliga, Santos Jiménez-Galanes, Héctor Guadalajara Labajo, Damián García Olmo and Pedro Villarejo Campos
Cancers 2025, 17(7), 1209; https://doi.org/10.3390/cancers17071209 - 2 Apr 2025
Viewed by 269
Abstract
Objectives: Inflammatory fibroid polyps, also known as Vanek’s tumors, are rare benign lesions of the gastrointestinal tract. Although the exact cause remains unclear, several theories suggest an association with inflammatory processes and genetic factors. This study aims to present the largest cohort of [...] Read more.
Objectives: Inflammatory fibroid polyps, also known as Vanek’s tumors, are rare benign lesions of the gastrointestinal tract. Although the exact cause remains unclear, several theories suggest an association with inflammatory processes and genetic factors. This study aims to present the largest cohort of inflammatory fibroid polyp cases to date, analyzing their clinical presentation, diagnostic methods, and treatment approaches. Materials and methods: A retrospective multicentric analysis was conducted on 67 patients diagnosed with inflammatory fibroid polyps between 2013 and 2023 across four hospitals. Clinical data regarding tumor location, size, symptoms, and treatment were collected. Non-parametric statistical tests, including the chi-square test, Cramér’s V coefficient, and the Mann–Whitney U test, were used to identify association between tumor characteristics, location, and treatment outcomes. Results: The cohort included 67 patients (58.2% female, median age 60 years). The stomach was the most common tumor site (47.8%), followed by the colon (32.8%), and small intestine (10.4%). The majority of patients (73.1%) were asymptomatic, while 9% experienced intestinal obstruction, all of which were located in the small intestine. Endoscopic resection was successful in 77.6% of cases, but surgical intervention was more frequently required for tumors in the small intestine. A significant association was found between larger tumor size, emergency presentation, intestinal location, and the need for surgery. Conclusions: Inflammatory fibroid polyps are commonly managed with endoscopic resection, particularly in gastric and colonic locations. However, small intestinal tumors more often need surgical treatment, especially when presenting with complications like intestinal obstruction. Full article
(This article belongs to the Special Issue Gastrointestinal Cancer Surgery)
18 pages, 4056 KiB  
Article
Does Total Neoadjuvant Therapy Impact Surgical Precision in Total Mesorectal Excision? A Nationwide Survey of the Experiences of Expert Surgeons
by Tarkan Jäger, Matthias Zitt, Stefan Riss, Jaroslav Presl, Philipp Schredl, Daniel Neureiter, Jan Philipp Ramspott, Peter Tschann, Walter Brunner, Hermann Nehoda, Gerd Pressl, Klemens Rohregger, Robert Sucher, Gerhard Jenic, Andreas Heuberger, Reinhold Kafka-Ritsch, Jörg Tschmelitsch, Lukas Schabl, Isabella Dornauer, Florentina Dermuth, Karin Rokitte, Franz Singhartinger, Josef Holzinger, Ingmar Königsrainer, Klaus Emmanuel and Felix Aigneradd Show full author list remove Hide full author list
Cancers 2025, 17(2), 283; https://doi.org/10.3390/cancers17020283 - 17 Jan 2025
Viewed by 1223
Abstract
Background: The treatment of locally advanced rectal cancer (LARC) has steadily progressed over the past four decades, with recent focus shifting towards total neoadjuvant therapy (TNT). This survey aims to elucidate the perceived surgical challenges faced by Austrian colorectal surgeons performing total mesorectal [...] Read more.
Background: The treatment of locally advanced rectal cancer (LARC) has steadily progressed over the past four decades, with recent focus shifting towards total neoadjuvant therapy (TNT). This survey aims to elucidate the perceived surgical challenges faced by Austrian colorectal surgeons performing total mesorectal excision (TME), focusing on the increased complexity and surgical difficulty introduced by intensified treatment regimens. Methods: A comprehensive survey was conducted among Austrian colorectal surgeons to explore various aspects of managing and performing TME following TNT. The survey included questions on the general management of LARC within their institutions and utilized a five-point Likert scale to assess the respondents’ perceptions and experiences regarding surgical precision and post-operative morbidity associated with TNT. Results: A total of 31 surgeons (54% response rate) completed the survey. Regarding multidisciplinary therapy preferences, 56% of respondents preferred conventional neoadjuvant therapy regimens, with 32% favoring chemoradiotherapy and 24% opting for short-course radiotherapy, while 31% chose TNT. The majority of respondents (65%) reported quality differences in tissue dissection during TME following TNT, with 57% experiencing difficulties in identifying tissue planes and 47% noting increased tissue fragility. Increased bleeding was reported by 32% of respondents. In cases of regrowth after a watch-and-wait approach, 64% observed quality changes in tissue dissection, and 47% noted tissue fragility. Conclusions: The survey results indicate that TNT impairs surgical precision due to changes in tissue quality and challenges in identifying surgical planes. Given the critical importance of surgical precision in achieving low local recurrence rates in mid-to-low LARC, these challenges could significantly impact patient outcomes. Further prospective studies are required to elucidate the extent of these effects. Full article
(This article belongs to the Special Issue Gastrointestinal Cancer Surgery)
►▼ Show Figures

Figure 1

15 pages, 1367 KiB  
Article
Real-World Outcomes for Localised Gastro-Oesophageal Adenocarcinoma Cancer Treated with Perioperative FLOT and Prophylactic GCSF Support in a Single Asian Centre
by Wanyi Kee, Kennedy Yao Yi Ng, Shun Zi Liong, Siqin Zhou, Sharon Keman Chee, Chiew Woon Lim, Justina Yick Ching Lam, Jeremy Tian Hui Tan, Hock Soo Ong, Weng Hoong Chan, Eugene Kee Wee Lim, Chin Hong Lim, Alvin Kim Hock Eng, Christabel Jing Zhi Lee and Matthew Chau Hsien Ng
Cancers 2024, 16(21), 3697; https://doi.org/10.3390/cancers16213697 - 1 Nov 2024
Cited by 2 | Viewed by 1321
Abstract
Background: Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) is a standard of care for patients with locally advanced gastro-oesophageal adenocarcinoma (GEA) in Western guidelines, but its use is limited in Asian patients. We report outcomes from a single Asian centre of perioperative FLOT with [...] Read more.
Background: Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) is a standard of care for patients with locally advanced gastro-oesophageal adenocarcinoma (GEA) in Western guidelines, but its use is limited in Asian patients. We report outcomes from a single Asian centre of perioperative FLOT with concomitant granulocyte colony-stimulating factor (GCSF) prophylaxis. Methods: A retrospective analysis of all 56 stage II to III GEA patients treated with perioperative FLOT at the National Cancer Centre Singapore between June 2017 and February 2024 was performed. All patients were discussed at a multidisciplinary tumour board, underwent preoperative laparoscopic staging, and received prophylactic GCSF with perioperative FLOT. Surgery was performed across four partner institutions. The primary endpoints were the tolerability of FLOT and pathological complete response (pCR). A univariate analysis of factors associated with survival and adverse events was also performed. Results: Overall, 33 patients (58.9%) completed eight cycles of pre- and postoperative FLOT, and 92.9% underwent resection. The commonest grade 3 to 4 adverse events (AEs) were diarrhoea (10.7%) and neutropenia (5.6%). The 30- and 90-day postoperative mortality rates were 0% and 1.9%, respectively. In resected tumours, the pCR was 15.4%. The median DFS was 27.5 months, but the median OS was not reached. The values for 1-, 2-, and 3-year DFS were 74.6%, 61.0%, and 46.5%, respectively. The values for 1-, 2-, and 3-year OS were 85.0%, 67.4%, and 61.0%, respectively. In the univariate analysis of patients who underwent resection, an ECOG status of 0 was associated with better DFS, while ypN0, R0 resection, and pathological stages 0-II were associated with better DFS and OS. Patients ≥ 65 years benefited from FLOT similarly to those <65 years in terms of DFS (HR 1.03; p = 0.940) and OS (HR 1.08; p = 0.869), with similar rates of grade 3 to 4 AEs. Patients with a higher housing index (HI) were less likely to experience ≥grade 3 AEs compared to those with a lower HI (OR 0.16, p = 0.029). Conclusions: This study presents a unique real-world Asian experience of perioperative FLOT with prophylactic GCSF use, with low rates of G3 to 4 neutropenia. The tolerability of FLOT was similar to that reported in Western populations. Furthermore, similar survival and rates of grade 3 to 4 AEs were observed in elderly patients. Patients of lower socioeconomic status were more likely to experience severe AEs, highlighting the need to proactively support vulnerable groups during treatment. Full article
(This article belongs to the Special Issue Gastrointestinal Cancer Surgery)
►▼ Show Figures

Figure 1

Other

Jump to: Research

15 pages, 1161 KiB  
Systematic Review
Rectovaginal Extra-Gastrointestinal Stromal Tumors (EGISTs): A Systematic Review of the Literature and a Pooled Survival Analysis
by Eleni Papamattheou, Ioannis Katsaros, Stavros P. Papadakos, Evangelos Lianos and Elissaios Kontis
Cancers 2025, 17(), 1382; https://doi.org/10.3390/cancers17081382 - 21 Apr 2025
Abstract
Background/Objectives: Extra-gastrointestinal stromal tumors (EGISTs) are rare mesenchymal tumors arising outside the gastrointestinal tract, making up <5% of all GISTs. Rectovaginal EGISTs are particularly uncommon, with limited available data. This study systematically reviews the clinicopathological features, management, and outcomes of rectovaginal EGISTs. [...] Read more.
Background/Objectives: Extra-gastrointestinal stromal tumors (EGISTs) are rare mesenchymal tumors arising outside the gastrointestinal tract, making up <5% of all GISTs. Rectovaginal EGISTs are particularly uncommon, with limited available data. This study systematically reviews the clinicopathological features, management, and outcomes of rectovaginal EGISTs. Methods: A systematic review of the English-language literature was conducted for studies on rectovaginal EGISTs (search date: 15 January 2025). Results: Thirty-one studies, including 40 female patients (mean age: 55.2 ± 15.4 years), met the inclusion criteria. Presenting symptoms included vaginal bleeding (24.3%), palpable mass (13.5%), constipation (10.8%), and abdominal pain (8.1%); however, the majority of patients (45.9%) were asymptomatic. Surgical excision was undertaken in 95% of patients, more often via local resection (61.1%). A high-grade mitotic index (>5/50 HPF) was noted in 63.2%. CD117, DOG-1, and vimentin was expressed in all cases, while CD34 was positive in 97.1%. Adjuvant therapy with tyrosine kinase inhibitors (TKIs) was administered in 57.5%, and neoadjuvant therapy was rare (8.6%). Recurrence occurred in 39.4% over a median follow-up of 40 ± 61.5 months, with a median disease-free survival (DFS) of 48 months. One death occurred 13 months postoperatively. Conclusions: Rectovaginal EGISTs are exceedingly rare and often asymptomatic, complicating preoperative diagnosis. Surgical resection remains the cornerstone of treatment, complemented by stage-specific neoadjuvant or adjuvant TKI therapy. The challenging location predisposes to recurrence, underscoring the need for further studies to optimize management and improve outcomes. Full article
(This article belongs to the Special Issue Gastrointestinal Cancer Surgery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop